Drug Type Fc fusion protein, Biosimilar |
Synonyms Aflibercept Biosimilar (Ivy Pharma, Inc.), 阿柏西普生物类似药(Ivy Pharma, Inc.), IVY-5790 + [1] |
Target |
Action inhibitors |
Mechanism PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetic macular oedema | Preclinical | United States | 01 Nov 2024 | |
| Retinal vein occlusion-related macular edema | Preclinical | United States | 01 Nov 2024 | |
| Wet age-related macular degeneration | Preclinical | United States | 01 Nov 2024 |






